Evidence map›Paper›PMID 42764990›Full record

ArticleActa pharmaceutica Sinica. B2026

Targeting the SETD2-FTO-KIT pathway as a pharmacological strategy for TKI-refractory GIST.

Zhi Li, Junju He, Zhen Cao, Shishan Zhou, Yongwei Zhu, Yumei Duan, Anfeng Jiang, Yidi Guan, Jie Gao, Jian Tian and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Zhi LiXiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Junju HeKey Laboratory of Molecular Radiation Oncology Hunan Province, Changsha 410008, China.
Zhen CaoKey Laboratory of Molecular Radiation Oncology Hunan Province, Changsha 410008, China.
Shishan ZhouDepartment of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China.
Yongwei ZhuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Yumei DuanDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, China.
Anfeng JiangDepartment of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China.
Yidi GuanKey Laboratory of Molecular Radiation Oncology Hunan Province, Changsha 410008, China.
Jie GaoKey Laboratory of Molecular Radiation Oncology Hunan Province, Changsha 410008, China.
Jian TianDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha 410008, China.
Liyu LiuKey Laboratory of Molecular Radiation Oncology Hunan Province, Changsha 410008, China.
Zhuoxian RongKey Laboratory of Molecular Radiation Oncology Hunan Province, Changsha 410008, China.
Heli LiuDepartment of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Xiaowei LiuDepartment of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, China.
Hengyi XiaoThe Lab of Aging Research, National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610093, China.
Yuezhen DengXiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Bin LiDepartment of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China.
Lunquan SunXiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosine kinase inhibitors (TKIs) have significantly improved outcomes in gastrointestinal stromal tumors (GIST), but acquired resistance remains a major clinical obstacle. The underlying mechanisms that sustain oncogenic KIT signaling in TKI-refractory GIST are not fully understood. Here, we identify a previously unrecognized epigenetic-epitranscriptomic regulatory axis involving SETD2, FTO, and KIT that promotes TKI resistance by stabilizing

Indexed as

EntacaponeFTOKITm6A RNA demethylationPhase I clinical trialSETD2Targeted therapyTyrosine kinase inhibitors (TKIs)-refractory GIST

Identifiers

PMID42764990
PMCPMC13589946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.